Vanda Pharmaceuticals Reaches Agreement with FDA
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vanda ( (VNDA) ) has issued an update.
On October 1, 2025, Vanda Pharmaceuticals Inc. announced a collaborative framework with the U.S. Food and Drug Administration to resolve disputes concerning its drugs, HETLIOZ® and tradipitant. This agreement includes expedited re-reviews of clinical holds and new drug applications, as well as pauses in ongoing legal and administrative proceedings, potentially impacting Vanda’s market positioning and regulatory strategy.
The most recent analyst rating on (VNDA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Vanda stock, see the VNDA Stock Forecast page.
Spark’s Take on VNDA Stock
According to Spark, TipRanks’ AI Analyst, VNDA is a Neutral.
Vanda Pharmaceuticals’ overall stock score reflects significant financial challenges, weak technical indicators, and unattractive valuation. Despite potential growth from new products and corporate events, operational inefficiencies and regulatory challenges weigh heavily on the stock.
To see Spark’s full report on VNDA stock, click here.
More about Vanda
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies to address high unmet medical needs and improve the lives of patients.
Average Trading Volume: 474,341
Technical Sentiment Signal: Hold
Current Market Cap: $290.1M
For detailed information about VNDA stock, go to TipRanks’ Stock Analysis page.
